Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer

Author:

Zhou Qian1ORCID,Liang Jinxia1,Yang Tong1,Liu Jin1,Li Bo12,Li Yingchang1,Fan Zhenzhen1ORCID,Wang Weida3,Chen Wensheng14,Yuan Sujing3,Xu Meng4,Xu Qigui5,Luan Zhidong5,Xia Zhongjun3,Zhou Penghui3ORCID,Huang Yadong6ORCID,Chen Liang46ORCID

Affiliation:

1. Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes and MOE Key Laboratory of Tumor Molecular Biology Institute of Life and Health Engineering College of Life Science and Technology Jinan University Guangzhou China

2. MOE Key Laboratory of Glucolipid Metabolic Diseases Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine College of Chinese Medicine Research Guangdong Pharmaceutical University Guangzhou China

3. State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China

4. Department of Oncology The First Affiliated Hospital Jinan University Guangzhou China

5. Translational medicine laboratory People’s Hospital of Yangjiang City Guangdong China

6. Guangdong Province Key Laboratory of Bioengineering Medicine Jinan University Guangzhou China

Funder

Fundamental Research Funds for the Central Universities

Publisher

EMBO

Subject

Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3